Literature DB >> 31659725

Cystic Fibrosis: Pathophysiology of Lung Disease.

Christelle Bergeron1, André M Cantin1,2.   

Abstract

Cystic fibrosis (CF) is a common, life-threatening, multisystemic, autosomal recessive disorder. In the last few years, giant steps have been made with regard to the understanding of CF pathophysiology, allowing the scientific community to propose mechanisms that cause the myriad of CF clinical manifestations. Following the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in 1989, the structure and function of the CFTR protein were described. Since then, more than 2,000 variants of the CFTR gene and their impact on the amount and function of the CFTR protein have been reported. The role of the CFTR protein as an ion channel transporting chloride and bicarbonate and its repercussions on different epithelial cell-lined organs and mucus are now better understood. Mechanisms behind susceptibility to infection in CF have also been proposed and include abnormalities in the composition, volume and acidity of the airway surface liquid, changes in the submucosal gland's anatomy and function, and deficiencies in the mucociliary clearance system. Numerous hypotheses explaining the excessive inflammatory response in CF are also debated and involve impaired mucociliary clearance, persistent hypoxia, lipid abnormalities, protease and antiprotease disproportion, and oxidant and antioxidant imbalance. The purpose of this review is to summarize our current knowledge of CF pathophysiology, including significant historic discoveries and most recent breakthroughs, and to improve understanding and awareness of this fatal disease. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Year:  2019        PMID: 31659725     DOI: 10.1055/s-0039-1694021

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  13 in total

1.  Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure.

Authors:  Kiera H Harwood; Rachel M McQuade; Andrew Jarnicki; Elena K Schneider-Futschik
Journal:  ACS Pharmacol Transl Sci       Date:  2022-06-10

Review 2.  Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy.

Authors:  Victor Emanuel Miranda Soares; Thiago Inácio Teixeira do Carmo; Fernanda Dos Anjos; Jonatha Wruck; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini; Débora Tavares de Resende E Silva
Journal:  Mol Cell Biochem       Date:  2021-09-16       Impact factor: 3.396

Review 3.  An update on the regulatory mechanisms of NLRP3 inflammasome activation.

Authors:  Seungwha Paik; Jin Kyung Kim; Prashanta Silwal; Chihiro Sasakawa; Eun-Kyeong Jo
Journal:  Cell Mol Immunol       Date:  2021-04-13       Impact factor: 11.530

4.  A medium composition containing normal resting glucose that supports differentiation of primary human airway cells.

Authors:  Rachel Morgan; Candela Manfredi; Kristen F Easley; Lionel D Watkins; William R Hunt; Steven L Goudy; Eric J Sorscher; Michael Koval; Samuel A Molina
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

Review 5.  Impact of Airway Inflammation on the Efficacy of CFTR Modulators.

Authors:  Carla M P Ribeiro; Martina Gentzsch
Journal:  Cells       Date:  2021-11-22       Impact factor: 6.600

6.  Transmission electron microscopy study of suspected primary ciliary dyskinesia patients.

Authors:  Mitra Rezaei; Amirali Soheili; Seyed Ali Ziai; Atefeh Fakharian; Hossein Toreyhi; Mihan Pourabdollah; Jahangir Ghorbani; Mahboobeh Karimi-Galougahi; Seyed Alireza Mahdaviani; Maryam Hasanzad; Alireza Eslaminejad; Hossein Ali Ghaffaripour; Saied Mahmoudian; Zahra Rodafshani; Maryam Sadat Mirenayat; Mohammad Varahram; Majid Marjani; Payam Tabarsi; Davood Mansouri; Hamid Reza Jamaati; Ali Akbar Velayati
Journal:  Sci Rep       Date:  2022-02-11       Impact factor: 4.379

7.  Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa From Cystic Fibrosis Patients.

Authors:  Giovanni Di Bonaventura; Veronica Lupetti; Fabio Verginelli; Sara Giancristofaro; Rosemary Barbieri; Giovanni Gherardi; Arianna Pompilio
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

Review 8.  CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis.

Authors:  Francesca Saluzzo; Luca Riberi; Barbara Messore; Nicola Ivan Loré; Irene Esposito; Elisabetta Bignamini; Virginia De Rose
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

Review 9.  New Therapies to Correct the Cystic Fibrosis Basic Defect.

Authors:  Christelle Bergeron; André M Cantin
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

10.  IRE1α Is a Therapeutic Target for Cystic Fibrosis Airway Inflammation.

Authors:  Emily A Hull-Ryde; John T Minges; Mary E B Martino; Takafumi Kato; Jacqueline L Norris-Drouin; Carla M P Ribeiro
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.